Selenium (Se) is a particularly promising cancer chemopreventive agent. We have been investigating the effects of oral Se supplementation on the metabolism of two forms of Se, selenomethionine (SeMet) and selenite (Sel), by comparing kinetics for 4-mo before (PK1) and after (PK2) 2 yrs of supplementation with 200 ug of Se as SeMet. For each pharmacokinetic study, thirty free-living subjects (15 M, 15 F) received 2 oral doses of 2 stable isotope tracers, 150 ug of 74Se as SeMet and 150 ug of 76Se as sodium selenite (Sel). A compartmental model requiring ten kinetically distinct compartments in plasma and recirculation of tracer through liver and tissues was developed using data from PK1. The model was then applied to data from PK2. By using the relative absorption of Sel to Se Met and excretion rates of total Se in urine and feces, we were able to combine information on the kinetics of each form and predict the size of each plasma pool in each study. Based on data from 7 subjects, Se-supplementation increased total plasma Se from 132ng/ml to 252 ng/ml with notable increases in five of the plasma pools. Insights into Se metabolism from this investigation will be crucial to interpreting Se-intervention results, such as those of the 35,000+ male subject SELECT prostate cancer prevention trial.

This study determined whether a single 60-mg dose of ferrous sulfate interferes with fractional zinc absorption (FZA) at 7-9 wk of lactation. In a crossover design, 5 exclusively breast-feeding women were given either a single 60-mg iron supplement or no supplement. FZA was measured by analyzing zinc stable isotope tracers ((70)Zn and (67)Zn) in urine samples collected for 7 d after isotope dosing. A 0.7-micromol intravenous (IV) infusion of (70)Zn as ZnCl(2) in saline was followed by a 0.03-mmol oral dose of (67)Zn as ZnCl(2) given with a standardized meal. After a 7-d wash-out period, the supplement given was reversed and a second FZA measurement was taken. FZA was calculated from isotopic enrichments in urine measured by inductively coupled plasma mass spectrometry. Hemoglobin, plasma ferritin and transferrin receptor, and plasma 5'-nucleotidase, plasma zinc and erythrocyte zinc did not differ before the two measurements of zinc absorption. When women were given a single iron supplement, FZA was significantly lower, 21.7 +/- 1.7% compared with 26.9 +/- 2.6% when no supplement was given (P = 0.032). A single 60-mg iron dose significantly decreases FZA during early lactation.

Enriched stable isotopes used as tracers have proven to be valuable in studies of the absorption and metabolism of minerals. Unlike radioisotopes, they can be used in high-risk population groups such as infants, children, and pregnant or lactating women. Estimates of mineral absorption can be made from the oral administration of a single tracer or from two tracers, one given orally and the other intravenously (IV). It is possible to determine the metabolism of the mineral with modeling based on the amount of the tracer or tracers in different biological samples. One of the key decisions in studies of this type is determining which enriched isotope and what amount to use. An example is given of calculations to estimate and compare the amounts of tracers needed for an absorption study. Methods for calculating the amounts of tracer in oral and IV doses are presented, and limits of detection and quantitation are discussed in terms of percent of enrichment and related to isotope ratio measurement precision. A general review of the use of mass spectrometric instruments for quantifying various stable isotopes is given.

The efficacy of a chelating agent in binding a given metal in a biological system depends on the binding constants of the chelator for the particular metals in the system, the concentration of the metals, and the presence and concentrations of other ligands competing for the metals in question. In this study, we make a comparison of the in vitro binding constants for the chelator, ethylenediaminetetraacetic acid, with the quantitative urinary excretion of the metals measured before and after EDTA infusion in 16 patients. There were significant increases in lead, zinc, cadmium, and calcium, and these increases roughly corresponded to the expected relative increases predicted by the EDTA-metal-binding constants as measured in vitro. There were no significant increases in urinary cobalt, chromium, or copper as a result of EDTA infusion. The actual increase in cobalt could be entirely attributed to the cobalt content of the cyanocobalamin that was added to the infusion. Although copper did increase in the post-EDTA specimens, the increase was not statistically significant. In the case of magnesium, there was a net retention of approximately 85% following chelation. These data demonstrate that EDTA chelation therapy results in significantly increased urinary losses of lead, zinc, cadmium, and calcium following EDTA chelation therapy. There were no significant changes in cobalt, chromium, or copper and a retention of magnesium. These effects are likely to have significant effects on nutrient concentrations and interactions and partially explain the clinical improvements seen in patients undergoing EDTA chelation therapy.

Determining the fractional absorption (FA) of calcium using the incorporation into urine of stable isotopes given intravenously (IV) and orally has become a routine procedure. We investigated the FA of calcium in two groups of (2-3 mo) postpartum women lactating (LACT) (n = 6) and nonlactating (PPNL) (n = 6), and in never pregnant (NP) women (n = 7). The women consumed a controlled diet containing 30-33 mmol/d calcium (Ca) for 21 d. On d 7 of the controlled diet, the women received 0.05 mmol of 42Ca IV and 0.25 mmol 44Ca orally in milk. Urine samples (24-h) were collected for the next 14 d and morning blood samples were collected from fasting subjects before dosing and at 24 and 48 h after receiving the isotopes. Milk samples from the LACT women were collected from each feeding beginning 24 h before to 72 h after dosing. There were no significant differences in the FA of calcium as measured by stable isotope incorporation into urine (23.8 +/- 2.9%), serum (24.0 +/- 3.4%) or milk (23.6 +/- 3.6%) of LACT women. The fractional calcium absorption measured in urine of the postpartum women (LACT and PPNL, 23.8 +/- 2.9% and 25.0 +/- 3.3%, respectively) did not differ but was greater (P < 0.028) than that of the NP women (17.3 +/- 1.3%). The postpartum LACT and PPNL women had a reduced urinary excretion of calcium (P < 0.01) compared with the NP women. There was a significantly greater incorporation (P < 0.001) by LACT women of the oral isotope dose into milk than into urine. Calcium FA can be determined from incorporation of stable isotopes into breast milk and serum as well as urine.

Although dairy food intake is low among the Navajo people, hip fracture rates are lower than in Caucasians. Genetic differences in bone density have been cited as the reasons for low fracture rates among Native Americans and other segments of the population. However, more detailed examination of mineral intakes suggests that environmental factors may provide part of the explanation for the lower fracture rates. Cultural practices such as the addition of ash to traditional foods and the high mineral content of water may provide much higher intakes of bone-related minerals than food intake surveys have previously reported. As part of a larger study to assess overall intake of minerals related to bone health and other conditions, water samples were collected from the Navajo reservation. Duplicates were collected at least one week apart from 53 sites including wells, springs, taps, and storage barrels and analyzed by atomic absorption and inductively coupled plasma spectrometry for a number of minerals. For average intakes of 2 l/day, water could provide up to 212 mg of calcium, 150 mg of magnesium and 8 mg of zinc. The combined contribution of mineral intakes provided by the addition of juniper ash to traditional foods, not genetic differences, may partially explain the lower fracture rates of the Navajo people. Further research in this area is required to confirm this hypothesis.

In most readily accessible biological samples from humans, like blood, serum/plasma, urine, etc, the levels of chromium (Cr) are less than 1 ng/g, and in many cases closer to 0.1 ng/g. Only 3 analytical techniques have the required sensitivity to make measurements at these levels, namely, neutron activation analysis (NAA), mass spectrometry (MS), and graphite furnace atomic absorption spectrometry (GFAAS). The first 2 are not widely available, and the third is the one most susceptible to interferences from the sample matrix. At the sub-parts-per-billion level, collecting samples without contaminating them and generating sufficiently low analytical and reagent blanks become extremely important and difficult. For other determinations of Cr, eg, in diet components, foods and tissues, where the levels are often well above the ng/g level, the required sensitivity is less of a limitation, but contamination problems remain, and factors like sample processing and homogeneity become more important. Problems and precautions in Cr determinations are discussed, and means of accuracy verification are presented. A novel use of stable isotopes of Cr in an accurate, non-radioactive method of measuring blood volume is described, as well as a discussion of the future of Cr determinations using inductively-coupled plasma mass spectrometry. J. Trace Elem. Exp. Med. 12:99-109, 1999. Published 1999 Wiley-Liss, Inc.dagger

A method for the measurement of calcium isotopes (42Ca, 43Ca, and 44Ca) using quadrupole inductively coupled plasma mass spectrometry (ICP-MS) is described. Interferences from polyatomic ions such as 12C16O2+ and 40ArH2+ at the calcium masses are greatly minimized by operating the ICP-MS in the cool plasma mode. Relative standard deviations (RSD) for the 42Ca∶43Ca and 44Ca∶43Ca ratios were found to be about 0.25%. Sample preparation involved using ammonium oxalate at a pH of 8 to separate calcium from samples such as serum, urine, feces, and breast milk. The isotope ratio measurements were used to determine fractional absorption of calcium by a lactating woman after intravenous administration of 42Ca and ingestion of 44Ca.

To determine the fate and distribution of chromium during lactation, six lactating women (25-38 y old) were given three doses of the tracer 53Cr (7.55 micromol/d, or 400 microg/d) on days 1, 2, and 3 of the study. Diet records, blood samples taken while subjects were fasting, and 24-h composite milk and urine samples were collected from day 0 to day 6. Fasting blood samples, morning milk samples, and 24-h urine samples were also collected on days 8, 10, 15, 30, 60, and 90. 53Cr and natural and total chromium concentrations in biological fluids were measured with gas chromatography-mass spectrometry and total urinary chromium was measured with atomic-absorption spectrometry. 53Cr was detectable in serum 2 h after dosing and continued to be detected from day 30 to day 60. Changes in total serum chromium concentration in response to the oral dose suggested that chromium concentrations in blood were not tightly regulated. 53Cr was not detected in breast milk and no significant changes in natural chromium concentration in milk were observed in response to the oral doses, suggesting that breast-milk chromium concentrations are independent of intake. The estimated chromium intake of exclusively breast-fed infants was 2.5 nmol/d (0.13 microg/d), below the lower end of the range of estimated safe and adequate daily dietary intakes (10-40 microg/d) for infants 0-6 mo of age. The baseline chromium concentration in urine and the minimum 53Cr absorption in lactating women were comparable with values for nonpregnant, nonlactating subjects. Chromium losses in breast milk do not appear to be compensated for via increased absorption or decreased excretion.